Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gaucher Disease Type 1”

70 trials

Showing 20 of 70 results

Large-scale testing (Phase 3)Study completedNCT03485677
What this trial is testing

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Who this might be right for
Gaucher's Disease Type IGaucher's Disease Type III
Sanofi 57
Testing effectiveness (Phase 2)Study completedNCT00813865
What this trial is testing

A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients

Who this might be right for
Gaucher DiseaseType 1 Gaucher DiseaseGaucher Disease, Type 1
Amicus Therapeutics 8
Post-approval studies (Phase 4)Study completedNCT04120506
What this trial is testing

Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)

Who this might be right for
Gaucher Disease, Type 1
Shaare Zedek Medical Center 15
Large-scale testing (Phase 3)Study completedNCT00553631
What this trial is testing

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

Who this might be right for
Gaucher Disease, Type 1
Shire 34
Large-scale testing (Phase 3)WithdrawnNCT01161914
What this trial is testing

The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

Who this might be right for
Gaucher Disease
ISU Abxis Co., Ltd.
Not applicableStudy completedNCT02416661
What this trial is testing

Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease

Who this might be right for
Lysosomal Storage DiseasesGaucher DiseaseSphingolipidoses
CENTOGENE GmbH Rostock 299
Not applicableLooking for participantsNCT06162338
What this trial is testing

The Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I

Who this might be right for
Gaucher Disease Type I
He Huang 3
Not applicableStudy completedNCT01136304
What this trial is testing

Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)

Who this might be right for
Gaucher Disease
University Research Foundation for Lysosomal Storage Diseases, Inc. 173
Testing effectiveness (Phase 2)Looking for participantsNCT05487599
What this trial is testing

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Who this might be right for
Gaucher DiseaseGaucher Disease, Type 1
Prevail Therapeutics 15
Not applicableStudy completedNCT02053896
What this trial is testing

A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease

Who this might be right for
Gaucher Disease
ISU Abxis Co., Ltd. 5
Testing effectiveness (Phase 2)Looking for participantsNCT06818838
What this trial is testing

A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease

Who this might be right for
Gaucher Disease Type 1
Lingyi Biotech Co., Ltd. 12
Early research (Phase 1)Study completedNCT00001410
What this trial is testing

PEG-Glucocerebrosidase for the Treatment of Gaucher Disease

Who this might be right for
Gaucher's Disease
National Institute of Mental Health (NIMH) 18
Post-approval studies (Phase 4)Study completedNCT02574286
What this trial is testing

Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

Who this might be right for
Gaucher Disease
Shire 21
Post-approval studies (Phase 4)WithdrawnNCT03021941
What this trial is testing

Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease

Who this might be right for
Type 1 Gaucher Disease
Pfizer
Testing effectiveness (Phase 2)Active Not RecruitingNCT04411654
What this trial is testing

Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

Who this might be right for
Gaucher Disease, Type 2
Prevail Therapeutics 7
Not applicableStudy completedNCT05702814
What this trial is testing

A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition

Who this might be right for
Gaucher Disease
Takeda 125
Testing effectiveness (Phase 2)Study completedNCT00433147
What this trial is testing

AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

Who this might be right for
Gaucher Disease, Type 1Type 1 Gaucher DiseaseGaucher Disease
Amicus Therapeutics 30
Testing effectiveness (Phase 2)Study completedNCT06050967
What this trial is testing

A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy.

Who this might be right for
Gaucher Disease Type 1
Hadassah Medical Organization 5
Early research (Phase 1)Study completedNCT00004294
What this trial is testing

Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease

Who this might be right for
Gaucher's Disease
National Center for Research Resources (NCRR) 15
Testing effectiveness (Phase 2)Study completedNCT03950050
What this trial is testing

Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy

Who this might be right for
Gaucher Disease, Type 1
Shaare Zedek Medical Center 40
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation